The 2019 European Society of Cardiology guidelines on diabetes, prediabetes, and cardiovascular diseases [25], the 2019 Heart Failure Association (HFA) position paper on the role and safety of new glucose-lowering medications [26], and the HFA clinical practice update on HF [27] recommend SGLT2 inhibitors to prevent HF hospitalization in patients with T2DM. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.